23 / 25
•
RAS
MAF can be easily detected in plasma using BEAMing tecnology.
•
A real-time quantification of
RAS
-mutant ctDNA MAFs may better define patient
prognosis than traditional clinicopathological factors.
•
RAS
MAF did not correlate with tumor location or tumor burden.
•
RAS
MAF was confirmed as a prognostic factor in 1st and 2nd line of treatment
for mCRC.
•
The underlying biological or molecular mechanisms that contribute to or
modulate plasma MAFs are still to be determined.
Conclusions